—Scannable Technology Grants Patients Access to Descriptions, Reviews
and Dosing Information for Evolve Formulas Products—
DENVER–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24NSHS&src=ctag” target=”_blank”gt;$NSHSlt;/agt;–NanoSphere
Health Sciences, Inc. (CSE:NSHS) (OTC:NSHSF), the biotechnology
leader behind the patented NanoSphere Delivery System™, today announced
the launch of its new, DoseCode-enabled Evolve
Formulas products in the Colorado market, leveraging industry-first
technology from Denver-based healthcare startup Gofire.
The Gofire DoseCode is a branded QR code attached to exclusive
plant-based medical products found in hundreds of retailers across
Colorado. When patients download the Gofire app, they can use their
phones to scan the DoseCode on Evolve Formulas products, allowing them
to access and save detailed descriptions, anonymous patient reviews and
ratings, complete batch and lab testing information, as well as dosing
recommendations from a community of peers who are also seeking relief.
Through an anonymous, secure personal profile, patients can use the app
to track their own results, document their top-rated products and record
“Powered by the groundbreaking NanoSphere Delivery System™, Evolve
Formulas products deliver unparalleled results in precise and consistent
dosages. Utilizing the Gofire DoseCode will enable Evolve patients to
see firsthand our exceptional lab results and to track and build a
reliable experience,” said Robert Sutton, Chairman and CEO of NanoSphere
Health Sciences. “Through our complementary technologies, NanoSphere
looks forward to joining Gofire in educating patients on product
selection and controlled dosing to help unlock the maximum therapeutic
benefits of plant-based medicine.”
DoseCode-enabled Evolve Formulas products—including the Transdermal
NanoSerum™ THC and Transdermal NanoSerum™ CBD with Resveratrol—will hit
dispensary shelves across Colorado next week.
For more information on Nanosphere Health Sciences, Inc. or to schedule
an interview, please contact Gabrielle Wesseldyk at [email protected]
NanoSphere’s Commitment to Licensing IP
NanoSphere launched its IP licensing program in 2015 and is entertaining
several licensing opportunities via a rigorous evaluation process. For
more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/
NanoSphere Health Sciences, Inc. is a biotechnology firm specializing in
the creation of the patented NanoSphere Delivery System™, a
revolutionary platform using nanotechnology in the biodelivery of
supplements, nutraceuticals and over-the-counter medications for the
cannabis, pharmaceutical and animal health industries, and beyond.
Nanosphere’s ‘Evolve Formulas’ line of products offer the world’s first
and only scientifically proven nanoparticle delivery system in cannabis.
For more information on Evolve Formulas, visit https://www.evolveformulas.com/.
Follow us on Facebook,
The Canadian Securities Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statement Caution
This news release includes forward looking statements that are
subject to assumptions, risks and uncertainties. Statements in this news
release which are not purely historical are forward looking statements,
including without limitation any statements concerning the Company’s
intentions, plans, estimates, expectations or beliefs regarding the
future. Although the Company believes that any forward looking
statements in this news release are reasonable, there can be no
assurance that any such forward looking statements will prove to be
accurate. The Company cautions readers that all forward looking
statements, including without limitation those relating to the Company’s
future operations and business prospects, are based on assumptions none
of which can be assured, and are subject to certain risks and
uncertainties that could cause actual events or results to differ
materially from those indicated in the forward looking statements.
Readers are advised to rely on their own evaluation of such risks and
uncertainties and should not place undue reliance on forward looking
statements. Any forward looking statements are made as of the date of
this news release, and the Company assumes no obligation to update the
forward looking statements, or to update the reasons why actual events
or results could or do differ from those projected in the forward
looking statements, whether as a result of new information, future
events or otherwise.
Gabrielle Wesseldyk[email protected]212-255-0945
On behalf of the BoardRobert Sutton, Chairman and CEOOffice:
Investors:Victor Goncalves, Executive Vice PresidentMobile: